1426535-45-6

Basic information

• Product Name: C₂₆H₂₁F₃N₄O₅S
• Synonyms: C₂₆H₂₁F₃N₄O₅S
• CAS NO: 1426535-45-6
• Molecular Weight: 558.538
• Mol File: 1426535-45-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₆H₂₁F₃N₄O₅S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₆H₂₁F₃N₄O₅S(1426535-45-6)
• EPA Substance Registry System: C₂₆H₂₁F₃N₄O₅S(1426535-45-6)

Safety Data

• Hazardous Substances Data: 1426535-45-6(Hazardous Substances Data)

Upstream product

• 2001-32-3 3-(2-nitrophenyl)propionic acid 
• 169590-42-5 4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide 
• 3958-60-9 2-nitrophenylmethyl bromide 

Downstream Products

• 169590-42-5 4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide 

Relevant articles and documents

A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib

Celecoxib is a COX-2 inhibitor drug that can be used to reduce the risk of colorectal adenocarcinoma. Glucocorticoids are used in the treatment of inflammatory bowel disease. A limitation to the use of both drug types is that they undergo absorption from the intestinal tract with serious side effects. The prodrug systems introduced here involve forming a nitro-substituted acylsulfonamide group in the case of celecoxib and a nitro-substituted 21-ester for the glucocorticoids. Drug release is triggered by the nitro reductase action of the colonic microflora, liberating a cyclization competent species. The release of the active parent drugs was evaluated in vitro using Clostridium perfringens and epithelial transport through Caco-2 monolayer evaluation was carried out to estimate the absorption properties of the prodrugs compared to the parental drugs.